Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
The Molecular Imaging Program at Stanford (MIPS) is committed to being at the forefront of medical imaging and is in the midst of the development of new molecular tracers that target specific cancer cells, and using these tracers as a possible vessel for delivery of therpeutic medications to malignant cells. Potential new tracers will be synthesized at the new cyclotron located on the Stanford Medical Center campus and include exciting agents such as FLT for lung cancer, 11C-Choline and 11C-Acetate for prostate cancer.